TY - JOUR T1 - Introductions and early spread of SARS-CoV-2 in the New York City area JF - medRxiv DO - 10.1101/2020.04.08.20056929 SP - 2020.04.08.20056929 AU - Ana S. Gonzalez-Reiche AU - Matthew M. Hernandez AU - Mitchell Sullivan AU - Brianne Ciferri AU - Hala Alshammary AU - Ajay Obla AU - Shelcie Fabre AU - Giulio Kleiner AU - Jose Polanco AU - Zenab Khan AU - Bremy Alburquerque AU - Adriana van de Guchte AU - Jayeeta Dutta AU - Nancy Francoeur AU - Betsaida Salom Melo AU - Irina Oussenko AU - Gintaras Deikus AU - Juan Soto AU - Shwetha Hara Sridhar AU - Ying-Chih Wang AU - Kathryn Twyman AU - Andrew Kasarskis AU - Deena Rose Altman AU - Melissa Smith AU - Robert Sebra AU - Judith Aberg AU - Florian Krammer AU - Adolfo GarcĂ­a-Sarstre AU - Marta Luksza AU - Gopi Patel AU - Alberto Paniz-Mondolfi AU - Melissa Gitman AU - Emilia Mia Sordillo AU - Viviana Simon AU - Harm van Bakel Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/04/11/2020.04.08.20056929.abstract N2 - New York City (NYC) has emerged as one of the epicenters of the current SARS-CoV2 pandemic. To identify the early events underlying the rapid spread of the virus in the NYC metropolitan area, we sequenced the virus causing COVID19 in patients seeking care at one of the hospitals of the Mount Sinai Health System. Phylogenetic analysis of 84 distinct SARS-CoV2 genomes indicates multiple, independent but isolated introductions mainly from Europe and other parts of the United States. Moreover, we find evidence for community transmission of SARS-CoV2 as suggested by clusters of related viruses found in patients living in different neighborhoods of the city.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe Research reported in this paper was supported by the Office of Research Infrastructure of the National Institutes of Health (NIH) under award numbers S10OD018522 and S10OD026880 as well as institutional funds. Protocols established for this study were in part based on influenza virus sequencing protocols established with the support of CRIP (Center for Research on Influenza Pathogenesis), an NIH funded Center of Excellence for Influenza Research and Surveillance (CEIRS, contract number HHSN272201400008C). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSARS-CoV-2 genome sequencing data for all study isolates has been deposited in GISAID. https://www.gisaid.org/ ER -